Premier journal of science.
December 3, 2024
Kanwal Shabir
Background Anxiety disorders are increasingly prevalent among young adults. Traditional treatment options often fall short, and many patients live with treatment-resistant anxiety. Psilocybin is a psychedelic compound that has gained attention for its therapeutic potential against anxiety when used in microdoses. Objective This review aims to evaluate the emerging evidence on psilocybin...
CNS Spectrums
December 1, 2024
Mauro Scala, Chiara Fabbri, Paolo Fusar‐poli et al.
8 citations
The revival of psilocybin in psychopharmacological research heralds a potential paradigm shift for treating mood and anxiety disorders, and other psychiatric conditions beyond the psychotic spectrum. This critical review evaluates current evidence on psilocybin's efficacy, juxtaposing potential benefits with the practical aspects of psychedelic-assisted psychotherapy (PAP) and the...
November 21, 2024
Larissa Rocha
<p><strong>Depression and anxiety are two of the most predominant mental disorders and leading causes of disability. The World Health Organization estimated that 3.8% of the world's population suffers from depression, and between 0.4% and 3.6% have an anxiety spectrum diagnosis. Psychedelics, particularly psilocybin, have been extensively studied as new and promising treatments, showing...
Current Topics in Behavioral Neurosciences
October 23, 2024
Grace Viljoen, Felix Betzler
5 citations
There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety disorders, but very few studies have examined the inverse of this, that is, the potential for psychedelics to inflict anxiety and affective symptoms. A systematic literature search was performed and 39 papers were included in the final review to...
Molecular Psychiatry
October 11, 2024
Michal Brownstien, Michal Lazar, Alexander Botvinnik et al.
23 citations
Abstract Obsessive compulsive disorder (OCD) is a highly prevalent disorder that causes serious disability. Available treatments leave 40% or more of people with OCD significantly symptomatic. There is an urgent need for novel therapeutic approaches. Mice that carry a homozygous deletion of the SAPAP3 gene (SAPAP3 KO) manifest a phenotype of excessive self-grooming, tic-like head-body twitches...
Journal of Psychopharmacology
October 3, 2024
Charles Q. Choi, Danica E. Johnson, David C J Chen-Li et al.
11 citations
Posttraumatic stress disorder (PTSD) is a condition that can develop after a traumatic event, causing distressing symptoms, including intrusive re-experiencing symptoms, alterations in mood and cognition, and changes in arousal and reactivity. Few treatment options exist for patients who find conventional psychotherapy and pharmacotherapy to be inaccessible, ineffective, or intolerable. We...
Frontiers in Psychiatry
September 23, 2024
Zhan-Ming Shi, Yu-Ping Ning, Xin-Hu Yang et al.
21 citations
Objectives The purpose of this systematic review of randomized controlled trials (RCTs) was to evaluate the effectiveness, safety, and tolerability of psilocybin in adult patients with major depressive disorder (MDD). Methods A systematic search (up to September 14, 2023) was conducted for RCTs that examined the efficacy, safety, and tolerability of psilocybin in physically healthy adult...
Neurobiology of Learning and Memory
September 1, 2024
David S Jacobs, Alina P Bogachuk, Chloé L Le Moing et al.
4 citations
Psilocybin may provide a useful treatment for mood disorders including anxiety and depression but its mechanisms of action for these effects are not well understood. While recent preclinical work has begun to assess psilocybin's role in affective behaviors through innate anxiety or fear conditioning, there is scant evidence for its role in conflict between reward and punishment. The current...
The Journal of Clinical Psychiatry
August 25, 2024
Mark A Frye, Balwinder Singh, Scott Breitinger et al.
2 citations
A man with AUD achieves sobriety on treatment with an SSRI and naltrexone, but then stops taking the SSRI to participate in a psilocybin “ceremony.” What factors contributed to his subsequent relapse to alcohol use?
Journal of Natural Remedies
July 31, 2024
V Suresh, Jitendra Lakhani, R Balaraman
Cancer patients are more vulnerable to developing psychiatric disorders like anxiety and depression. These conditions give an additional burden leading to poor quality of life. The available antidepressant and antianxiety drugs are not very useful in improving quality of life by reducing anxiety and depressive episodes. Therefore, there is a need for good drugs to alleviate the psychiatric...